Filing Details

Accession Number:
0001140361-10-028673
Form Type:
4
Zero Holdings:
No
Publication Time:
2010-07-07 13:00:00
Reporting Period:
2010-07-06
Filing Date:
2010-07-07
Accepted Time:
2010-07-07 14:36:18
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
874716 Idexx Laboratories Inc IDXX In Vitro & In Vivo Diagnostic Substances (2835) 010393723
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1184149 W Jonathan Ayers One Idexx Drive
Westbrook ME 04092
Chairman, President & Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2010-07-06 50,000 $12.60 246,081 No 4 M Direct
Common Stock Disposition 2010-07-06 25,800 $60.36 220,281 No 4 S Direct
Common Stock Disposition 2010-07-06 14,925 $61.48 205,356 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2010-07-06 50,000 $0.00 50,000 $12.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
540,320 2012-01-28 No 4 M Direct
Footnotes
  1. Includes 107 shares acquired under the IDEXX Laboratories, Inc. Employee Stock Purchase Plan on 6/30/2010.
  2. The sale reported above was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 11/3/2009.
  3. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $60.01 to $61.00, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 3 and 4 to this Form 4.
  4. The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $61.02 to $62.00, inclusive.
  5. Grant of options to buy shares of common stock which vest in five equal annual installments, beginning on the first anniversary date (1/28/2003) of the date of grant.